ClinicalTrials.gg

Program

Leuprolide

Also written as “Leuprorelin”, “Leuprolide acetate” and “Leuprolide Acetate”.

Its studies are mostly in Prostatic Neoplasms · Puberty, Precocious · Alzheimer Disease · Endometriosis · Breast Neoplasms, led by 18 companies.

Furthest: phase 4, since Apr 23, 201538 company-led studies, 2 open or runningNext primary completion: Aug 30, 2029 (phase 4)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Takeda60 open or runningphase 4since Apr 23, 2015Oct 16, 2008none ahead
Abbott50 open or runningphase 3since Feb 20, 2008Mar 20, 2003none ahead
AbbVie30 open or runningphase 4since Jul 9, 2010Apr 24, 2008none ahead
Daewoong Pharmaceutical31 open or runningphase 4since Jul 3, 2012Jul 3, 2012none ahead
GP-Pharm30 open or runningphase 3since Aug 8, 2005Aug 8, 2005none ahead
Astellas Pharma20 open or runningphase 4since Jan 25, 2017Sep 19, 2006none ahead
Chong Kun Dang Pharmaceutical20 open or runningphase 1since May 23, 2016May 23, 2016none ahead
Johnson & Johnson20 open or runningphase 2since Jun 17, 2009Jun 17, 2009none ahead
Oakwood Laboratories20 open or runningphase 3since Jan 26, 2004Jan 26, 2004none ahead
Voyager Pharmaceutical20 open or runningphase 2since Jun 25, 2003Jun 25, 2003none ahead
bharat-serums-and-vaccines-limited10 open or runningphase 3since May 31, 2021May 31, 2021none ahead
dongkook-pharmaceutical-co-ltd10 open or runningphase 3since Jun 13, 2024Jun 13, 2024none ahead
enteris-biopharma-inc10 open or runningphase 2since Oct 15, 2021Oct 15, 2021none ahead
Lee's Pharmaceutical10 open or runningno phasesince Aug 30, 2018Aug 30, 2018none ahead
LG Chem11 open or runningphase 4since Jul 6, 2026Jul 6, 2026Aug 30, 2029phase 4 · NCT07710430
peptron-inc10 open or runningphase 1since Mar 2, 2021Mar 2, 2021none ahead
tolmar-inc10 open or runningphase 3since May 5, 2015May 5, 2015none ahead
zodiac-produtos-farmaceuticos-s-a10 open or runningphase 4since Mar 11, 2022Mar 11, 2022none ahead

Also a collaborator on its studies: parexel.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 24 studies since Mar 20, 2003.

  1. May 5, 2015tolmar-inc's first study: phase 3 study in Puberty, PrecociousNew to tolmar-inctolmar-inc · NCT02452931 · 64 enrolled · United States, Argentina, Canada and more
  2. May 23, 2016Chong Kun Dang Pharmaceutical's first study: phase 1 study in Postmenopausal DisorderNew to Chong Kun Dang PharmaceuticalChong Kun Dang Pharmaceutical · NCT03233932 · 13 enrolled · Korea, Republic of
  3. Jan 12, 2017Phase 1 study in Prostatic NeoplasmsDaewoong Pharmaceutical · NCT03029533 · 44 enrolled
  4. Jan 25, 2017Phase 4 study in Prostatic NeoplasmsAstellas Pharma · NCT03035032 · 107 enrolled · Hong Kong, Indonesia, Malaysia and more
  5. Aug 30, 2018Lee's Pharmaceutical's first study: no phase study in Prostatic NeoplasmsNew to Lee's PharmaceuticalLee's Pharmaceutical · NCT03662958 · 48 enrolled · China
  6. Oct 2, 2018Phase 3 study in Puberty, PrecociousAbbVie · NCT03695237 · 45 enrolled · United States, Puerto Rico
  7. Mar 2, 2021peptron-inc's first study: phase 1 study in Prostatic NeoplasmsNew to peptron-incpeptron-inc · NCT04783636 · 40 enrolled
  8. Apr 8, 2021Phase 1 study in Puberty, PrecociousChong Kun Dang Pharmaceutical · NCT04840745 · 32 enrolled · Korea, Republic of
  9. May 31, 2021bharat-serums-and-vaccines-limited's first study: phase 3 study in Advanced Prostate AdenocarcinomaNew to bharat-serums-and-vaccines-limitedbharat-serums-and-vaccines-limited · NCT04914195 · 155 enrolled · India
  10. Oct 15, 2021enteris-biopharma-inc's first study: phase 2 study in EndometriosisNew to enteris-biopharma-incenteris-biopharma-inc · NCT05096065 · 16 enrolled · United States
  11. Mar 11, 2022zodiac-produtos-farmaceuticos-s-a's first study: phase 4 study in Prostatic NeoplasmsNew to zodiac-produtos-farmaceuticos-s-azodiac-produtos-farmaceuticos-s-a · NCT05304169 · 48 enrolled · Brazil
  12. Aug 29, 2023Phase 3 study in Puberty, PrecociousDaewoong Pharmaceutical · NCT06025409 · 79 planned · Korea, Republic of
  13. Jun 13, 2024dongkook-pharmaceutical-co-ltd's first study: phase 3 study in Advanced Prostate CancerNew to dongkook-pharmaceutical-co-ltddongkook-pharmaceutical-co-ltd · NCT06490328 · 161 enrolled · South Korea
  14. Jul 6, 2026LG Chem's first study: phase 4 study in Puberty, PrecociousNew to LG ChemLG Chem · NCT07710430 · 43 planned · South Korea

Ahead

  1. Aug 30, 2029Primary completion: phase 4 study in Puberty, PrecociousLG Chem · NCT07710430

TargetBeta

GNRHR →read by rule
“Gonadotropin-releasing hormone receptor agonist; Gonadotropin-releasing hormone receptor agonist”ChEMBL 37, by rule

Other programs on GNRHR

ProgramCompanyFurthest phaseStudies
triptorelinruleIpsenphase 421
GoserelinruleAstraZenecaphase 414
linzagolixruleKissei Pharmaceuticalphase 314
GnRH Antagonist SHR7280Jiangsu HengRui Medicinephase 310
Gonadotropin-Releasing HormoneruleFerring Pharmaceuticalsphase 35
leuprolide mesylateruleforesee-pharmaceuticals-co-ltdphase 33

Studies

All 38 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07710430Puberty, Precocious · South Korea4RecruitingLG ChemAug 30, 202943
NCT06490328Advanced Prostate Cancer · South Korea3Completeddongkook-pharmaceutical-co-ltdJan 21, 2026161
NCT06025409Puberty, Precocious · Korea, Republic of3RecruitingDaewoong PharmaceuticalFeb 28, 202579
NCT05304169Prostatic Neoplasms · Brazil4Completedzodiac-produtos-farmaceuticos-s-aJun 15, 201848
NCT05096065Endometriosis · United States2UNKNOWNenteris-biopharma-incMay 202216
NCT04914195Advanced Prostate Adenocarcinoma · India3Completedbharat-serums-and-vaccines-limitedSep 29, 2022155
NCT04840745Puberty, Precocious · Korea, Republic of1UNKNOWNChong Kun Dang PharmaceuticalOct 202132
NCT04783636Prostatic Neoplasms1UNKNOWNpeptron-incJul 20, 202140
NCT03695237Puberty, Precocious · United States, Puerto Rico3CompletedAbbVieMay 6, 202145
NCT03662958Prostatic Neoplasms · China–UNKNOWNLee's PharmaceuticalOct 201848
NCT03035032Prostatic Neoplasms · Hong Kong, Indonesia, Malaysia and more4CompletedAstellas PharmaNov 19, 2019107
NCT03029533Prostatic Neoplasms1UNKNOWNDaewoong PharmaceuticalNov 201744
NCT03233932Postmenopausal Disorder · Korea, Republic of1CompletedChong Kun Dang PharmaceuticalJul 201713
NCT02452931Puberty, Precocious · United States, Argentina, Canada and more3Completedtolmar-incSep 5, 201864
NCT02427958Puberty, Precocious · China4CompletedTakedaNov 23, 2018307
NCT02085252Prostatic Neoplasms · France3CompletedTakedaNov 8, 2016116
NCT01634321Puberty, Precocious · Korea, Republic of4CompletedDaewoong PharmaceuticalAug 201263
NCT01546649Premenopausal Breast Cancer · Japan3CompletedTakedaDec 2014167
NCT01546623Prostatic Neoplasms · Japan3CompletedTakedaApr 2014160
NCT01415960Prostatic Neoplasms · United States3CompletedGP-PharmMay 2013163
NCT01161563Prostatic Neoplasms · United States4CompletedAbbVieApr 2011118
NCT01088529Prostatic Neoplasms · United States2CompletedJohnson & JohnsonMar 201366
NCT00924469Prostatic Neoplasms · United States2CompletedJohnson & JohnsonFeb 201258
NCT00817739Prostatic Neoplasms2CompletedTakedaSep 2005341
NCT00776074Leiomyoma2CompletedTakedaJul 200780
NCT00667446Puberty, Precocious · United States, Puerto Rico3CompletedAbbVieOct 201272
NCT00660010Puberty, Precocious · United States3CompletedAbbottApr 200955
NCT00635817Puberty, Precocious · United States, Puerto Rico3CompletedAbbottJan 201084
NCT00630799Prostatic Neoplasms · United States3TerminatedGP-PharmApr 200920
NCT00626431Prostatic Neoplasms · United States3CompletedAbbottAug 2009310
NCT00598312Prostatic Neoplasms · United States3CompletedOakwood LaboratoriesAug 2008201
NCT00378690Prostatic Neoplasms · Belgium, Czech Republic, Finland and more3CompletedAstellas PharmaJun 2011706
NCT00275262Hodgkin Disease · United States2TerminatedAbbottFeb 200925
NCT00128531Prostatic Neoplasms · United States, Austria, Czech Republic and more3CompletedGP-Pharm120
NCT00076531Prostatic Neoplasms3CompletedOakwood LaboratoriesNov 2004
NCT00076440Alzheimer Disease · United States2CompletedVoyager PharmaceuticalMar 200790
NCT00063310Alzheimer Disease · United States2CompletedVoyager PharmaceuticalFeb 200690
NCT00056654Prostatic Neoplasms · United States–CompletedAbbottJul 2004164

How it is read

Names in the registry

  • “Leuprorelin”, 4 entries
  • “Leuprolide acetate”, 4 entries
  • “Leuprolide”, 2 entries
  • “Leuprolide Acetate”, 2 entries
  • “TAP-144-SR(6M)”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.